Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Liabilities - Leasing Arrangements
Deferred Tax Liabilities - Leasing Arrangements at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesLeasingArrangements.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax liabilities - leasing arrangements of $4.22M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements increased by 2983.2% year-over-year, from $137K to $4.22M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax liabilities - leasing arrangements has grown at a 95.5% compound annual growth rate (CAGR), from $148K to $4.22M.